AG真人官方

STOCK TITAN

[D] Cybin Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

Cybin Inc. (CYBN) filed a Form D announcing the completion of a Rule 506(b) private placement. The Ontario-based psychedelic therapeutics company sold $50 million in a mix of debt securities, warrants/options, and underlying shares. The first sale occurred on 30 June 2025 and the offering will not extend beyond one year. All of the targeted amount has been placed, leaving $0 remaining.

Key terms

  • Total offering size: $50,000,000
  • Securities type: Debt plus equity-linked instruments
  • Number of investors: 1 (accredited status not disclosed)
  • Sales commissions: $2,670,000 (Joseph Gunnar & Co., LLC)
  • Finder鈥檚 fees: $0
  • Proceeds earmarked for insiders: $0

The issuer declined to disclose revenue or asset size. The financing adds fresh capital without immediate payments to executives or directors and is not tied to a merger or acquisition. The exemption selected (Rule 506(b)) restricts general solicitation and requires sales only to accredited investors or up to 35 non-accredited sophisticated purchasers.

Cybin Inc. (CYBN) ha presentato un Modulo D annunciando il completamento di un collocamento privato secondo la Regola 506(b). La societ脿 canadese con sede in Ontario specializzata in terapie psichedeliche ha venduto 50 milioni di dollari attraverso un mix di strumenti di debito, warrant/opzioni e azioni sottostanti. La prima vendita 猫 avvenuta il 30 giugno 2025 e l'offerta non si estender脿 oltre un anno. L'intero importo previsto 猫 stato collocato, lasciando un residuo pari a 0 dollari.

Termini chiave

  • Dimensione totale dell'offerta: 50.000.000 dollari
  • Tipologia di strumenti: debito e strumenti collegati all'equity
  • Numero di investitori: 1 (stato accreditato non rivelato)
  • Commissioni di vendita: 2.670.000 dollari (Joseph Gunnar & Co., LLC)
  • Commissioni per intermediari: 0 dollari
  • Proventi destinati a insider: 0 dollari

L'emittente non ha rivelato dati su ricavi o patrimonio. Il finanziamento introduce nuovo capitale senza pagamenti immediati a dirigenti o amministratori ed 猫 non collegato a fusioni o acquisizioni. L'esenzione scelta (Regola 506(b)) limita la sollecitazione generale e prevede vendite solo a investitori accreditati o fino a 35 acquirenti sofisticati non accreditati.

Cybin Inc. (CYBN) present贸 un Formulario D anunciando la finalizaci贸n de una colocaci贸n privada bajo la Regla 506(b). La empresa de terapias psicod茅licas con sede en Ontario vendi贸 50 millones de d贸lares mediante una combinaci贸n de valores de deuda, warrants/opciones y acciones subyacentes. La primera venta tuvo lugar el 30 de junio de 2025 y la oferta no se extender谩 m谩s all谩 de un a帽o. Se ha colocado la totalidad del monto objetivo, quedando 0 d贸lares restantes.

T茅rminos clave

  • Tama帽o total de la oferta: 50.000.000 d贸lares
  • Tipo de valores: deuda e instrumentos vinculados a capital
  • N煤mero de inversores: 1 (estatus acreditado no revelado)
  • Comisiones de venta: 2.670.000 d贸lares (Joseph Gunnar & Co., LLC)
  • Honorarios de intermediarios: 0 d贸lares
  • Fondos destinados a personas internas: 0 d贸lares

El emisor no divulg贸 ingresos ni tama帽o de activos. La financiaci贸n aporta capital fresco sin pagos inmediatos a ejecutivos o directores y no est谩 vinculada a una fusi贸n o adquisici贸n. La exenci贸n seleccionada (Regla 506(b)) restringe la solicitud general y requiere ventas solo a inversores acreditados o hasta 35 compradores sofisticados no acreditados.

Cybin Inc. (CYBN)鞚 Rule 506(b) 靷 氚滍枆 鞕勲毳� 鞎岆Μ電� Form D毳� 鞝滌稖頄堨姷雼堧嫟. 鞓儉毽槫鞐� 氤胳偓毳� 霊� 靷澊韨る嵏毽� 旃橂鞝� 須岇偓電� 毂勲 歃濌秾, 鞗岆煱韸�/鞓奠厴, 旮办磮 欤检嫕鞚� 順柬暕頃橃棳 5,000毵� 雼煬毳� 韺愲Г頄堨姷雼堧嫟. 觳� 韺愲Г電� 2025雲� 6鞗� 30鞚�鞐� 鞚措(鞏挫鞙茧┌, 瓿惦電� 1雲勳潉 齑堦臣頃橃 鞎婌姷雼堧嫟. 氇╉憸 旮堨暋 鞝勳暋鞚� 氚办爼霅橃柎 雮潃 旮堨暋鞚 0雼煬鞛呺媹雼�.

欤检殧 臁瓣贝

  • 齑� 瓿惦 攴滊: 50,000,000雼煬
  • 歃濌秾 鞙犿槙: 攵毂� 氚� 欤检嫕 鞐瓣硠 靸來拡
  • 韴瀽鞛� 靾�: 1氇� (鞚胳 靸來儨 氙戈车臧�)
  • 韺愲Г 靾橃垬耄�: 2,670,000雼煬 (Joseph Gunnar & Co., LLC)
  • 欷戧皽 靾橃垬耄�: 0雼煬
  • 雮措秬鞛� 氚办爼 靾橃澋: 0雼煬

氚滍枆靷姅 毵れ稖鞚措倶 鞛愳偘 攴滊毳� 瓿店皽頃橃 鞎婌晿鞀惦媹雼�. 鞚措矆 鞛愱笀 臁半嫭鞚 瓴届榿歆勳澊雮� 鞚挫偓鞐愱矊 歃夑皝鞝侅澑 歆旮� 鞐嗢澊 鞁犼窚 鞛愲掣鞚� 於旉皜頃橂┌, 頃╇硲鞚措倶 鞚胳垬鞕 甏霠澊 鞐嗢姷雼堧嫟. 靹犿儩霅� 氅挫牅 臁绊暛(Rule 506(b))鞚 鞚茧皹 氇鞚� 鞝滍暅頃橂┌, 鞚胳 韴瀽鞛� 霕愲姅 斓滊寑 35氇呾潣 牍勳澑歃� 瓿犼笁 韴瀽鞛愳棎瓴岆 韺愲Г毳� 項堨毄頃╇媹雼�.

Cybin Inc. (CYBN) a d茅pos茅 un formulaire D annon莽ant la cl么ture d鈥檜n placement priv茅 selon la r猫gle 506(b). La soci茅t茅 de th茅rapeutiques psych茅d茅liques bas茅e en Ontario a vendu 50 millions de dollars via un m茅lange de titres de dette, bons de souscription/options et actions sous-jacentes. La premi猫re vente a eu lieu le 30 juin 2025 et l鈥檕ffre ne s鈥櫭﹖endra pas au-del脿 d鈥檜n an. La totalit茅 du montant cibl茅 a 茅t茅 plac茅e, il reste donc 0 dollar.

Principaux termes

  • Taille totale de l鈥檕ffre : 50 000 000 dollars
  • Type de titres : dette et instruments li茅s aux actions
  • Nombre d鈥檌nvestisseurs : 1 (statut accr茅dit茅 non divulgu茅)
  • Commissions de vente : 2 670 000 dollars (Joseph Gunnar & Co., LLC)
  • Frais d鈥檃pporteurs d鈥檃ffaires : 0 dollar
  • Produit destin茅 aux initi茅s : 0 dollar

L鈥櫭﹎etteur a refus茅 de divulguer ses revenus ou la taille de ses actifs. Ce financement apporte de nouveaux capitaux sans paiements imm茅diats aux cadres ou administrateurs et n鈥檈st pas li茅 脿 une fusion ou acquisition. L鈥檈xemption choisie (r猫gle 506(b)) restreint la sollicitation g茅n茅rale et exige des ventes uniquement aux investisseurs accr茅dit茅s ou 脿 un maximum de 35 acheteurs sophistiqu茅s non accr茅dit茅s.

Cybin Inc. (CYBN) hat ein Formular D eingereicht und die Durchf眉hrung einer Privatplatzierung nach Regel 506(b) bekanntgegeben. Das in Ontario ans盲ssige Unternehmen f眉r psychedelische Therapien verkaufte 50 Millionen US-Dollar in einer Mischung aus Schuldtiteln, Warrants/Optionen und zugrunde liegenden Aktien. Der erste Verkauf erfolgte am 30. Juni 2025, und das Angebot wird nicht l盲nger als ein Jahr laufen. Der gesamte Zielbetrag wurde platziert, es verbleiben 0 US-Dollar.

Wichtige Bedingungen

  • Gesamtvolumen des Angebots: 50.000.000 US-Dollar
  • Art der Wertpapiere: Schulden plus aktiengebundene Instrumente
  • Anzahl der Investoren: 1 (Status akkreditiert nicht angegeben)
  • Verkaufsprovisionen: 2.670.000 US-Dollar (Joseph Gunnar & Co., LLC)
  • 痴别谤尘颈迟迟濒耻苍驳蝉驳别产眉丑谤别苍: 0 US-Dollar
  • Ertr盲ge f眉r Insider: 0 US-Dollar

Der Emittent verweigerte Angaben zu Umsatz oder Verm枚genswerten. Die Finanzierung bringt frisches Kapital ohne sofortige Zahlungen an F眉hrungskr盲fte oder Direktoren und ist nicht an eine Fusion oder 脺bernahme gebunden. Die gew盲hlte Befreiung (Regel 506(b)) schr盲nkt die allgemeine Werbung ein und erlaubt Verk盲ufe nur an akkreditierte Investoren oder bis zu 35 nicht akkreditierte, aber versierte K盲ufer.

Positive
  • $50 million in gross proceeds secured, bolstering Cybin鈥檚 cash position for ongoing development.
  • No insider payments disclosed, reducing potential conflicts of interest.
  • Reasonable commission rate of roughly 5.3%, indicating cost-effective capital raising.
Negative
  • Financing includes debt and warrant components, introducing leverage and future equity dilution.
  • Single-investor structure concentrates ownership and negotiation power.
  • Company declined to disclose revenue, limiting visibility into leverage capacity.

Insights

TL;DR: Cybin secures $50 M via private debt + warrants, strengthening liquidity but adding leverage and potential dilution.

The completed $50 million raise delivers meaningful cash for R&D and clinical programs without immediate insider payouts. Using debt alongside warrants implies future dilution and interest expense, but avoids an all-equity raise that could have pressured the share price today. A single investor simplifies negotiations yet concentrates counter-party risk. At 5.3% (2.67/50) selling cost, placement expenses are reasonable for a Rule 506(b) deal. Overall, the financing improves near-term funding capacity and signals investor confidence, though leverage metrics will need monitoring once terms are disclosed.

TL;DR: Form D shows compliance with Reg D; minimal governance red flags observed.

The filing adheres to Rule 506(b) requirements and discloses all executive and director relationships. No proceeds are directed to insiders, mitigating conflict-of-interest concerns. Commission disclosure is clear, and the absence of finder鈥檚 fees reduces related-party risk. Lack of revenue data limits transparency but is permissible under Reg D. Concentration in a single investor increases influence over company decisions, a point boards should address through covenant management.

Cybin Inc. (CYBN) ha presentato un Modulo D annunciando il completamento di un collocamento privato secondo la Regola 506(b). La societ脿 canadese con sede in Ontario specializzata in terapie psichedeliche ha venduto 50 milioni di dollari attraverso un mix di strumenti di debito, warrant/opzioni e azioni sottostanti. La prima vendita 猫 avvenuta il 30 giugno 2025 e l'offerta non si estender脿 oltre un anno. L'intero importo previsto 猫 stato collocato, lasciando un residuo pari a 0 dollari.

Termini chiave

  • Dimensione totale dell'offerta: 50.000.000 dollari
  • Tipologia di strumenti: debito e strumenti collegati all'equity
  • Numero di investitori: 1 (stato accreditato non rivelato)
  • Commissioni di vendita: 2.670.000 dollari (Joseph Gunnar & Co., LLC)
  • Commissioni per intermediari: 0 dollari
  • Proventi destinati a insider: 0 dollari

L'emittente non ha rivelato dati su ricavi o patrimonio. Il finanziamento introduce nuovo capitale senza pagamenti immediati a dirigenti o amministratori ed 猫 non collegato a fusioni o acquisizioni. L'esenzione scelta (Regola 506(b)) limita la sollecitazione generale e prevede vendite solo a investitori accreditati o fino a 35 acquirenti sofisticati non accreditati.

Cybin Inc. (CYBN) present贸 un Formulario D anunciando la finalizaci贸n de una colocaci贸n privada bajo la Regla 506(b). La empresa de terapias psicod茅licas con sede en Ontario vendi贸 50 millones de d贸lares mediante una combinaci贸n de valores de deuda, warrants/opciones y acciones subyacentes. La primera venta tuvo lugar el 30 de junio de 2025 y la oferta no se extender谩 m谩s all谩 de un a帽o. Se ha colocado la totalidad del monto objetivo, quedando 0 d贸lares restantes.

T茅rminos clave

  • Tama帽o total de la oferta: 50.000.000 d贸lares
  • Tipo de valores: deuda e instrumentos vinculados a capital
  • N煤mero de inversores: 1 (estatus acreditado no revelado)
  • Comisiones de venta: 2.670.000 d贸lares (Joseph Gunnar & Co., LLC)
  • Honorarios de intermediarios: 0 d贸lares
  • Fondos destinados a personas internas: 0 d贸lares

El emisor no divulg贸 ingresos ni tama帽o de activos. La financiaci贸n aporta capital fresco sin pagos inmediatos a ejecutivos o directores y no est谩 vinculada a una fusi贸n o adquisici贸n. La exenci贸n seleccionada (Regla 506(b)) restringe la solicitud general y requiere ventas solo a inversores acreditados o hasta 35 compradores sofisticados no acreditados.

Cybin Inc. (CYBN)鞚 Rule 506(b) 靷 氚滍枆 鞕勲毳� 鞎岆Μ電� Form D毳� 鞝滌稖頄堨姷雼堧嫟. 鞓儉毽槫鞐� 氤胳偓毳� 霊� 靷澊韨る嵏毽� 旃橂鞝� 須岇偓電� 毂勲 歃濌秾, 鞗岆煱韸�/鞓奠厴, 旮办磮 欤检嫕鞚� 順柬暕頃橃棳 5,000毵� 雼煬毳� 韺愲Г頄堨姷雼堧嫟. 觳� 韺愲Г電� 2025雲� 6鞗� 30鞚�鞐� 鞚措(鞏挫鞙茧┌, 瓿惦電� 1雲勳潉 齑堦臣頃橃 鞎婌姷雼堧嫟. 氇╉憸 旮堨暋 鞝勳暋鞚� 氚办爼霅橃柎 雮潃 旮堨暋鞚 0雼煬鞛呺媹雼�.

欤检殧 臁瓣贝

  • 齑� 瓿惦 攴滊: 50,000,000雼煬
  • 歃濌秾 鞙犿槙: 攵毂� 氚� 欤检嫕 鞐瓣硠 靸來拡
  • 韴瀽鞛� 靾�: 1氇� (鞚胳 靸來儨 氙戈车臧�)
  • 韺愲Г 靾橃垬耄�: 2,670,000雼煬 (Joseph Gunnar & Co., LLC)
  • 欷戧皽 靾橃垬耄�: 0雼煬
  • 雮措秬鞛� 氚办爼 靾橃澋: 0雼煬

氚滍枆靷姅 毵れ稖鞚措倶 鞛愳偘 攴滊毳� 瓿店皽頃橃 鞎婌晿鞀惦媹雼�. 鞚措矆 鞛愱笀 臁半嫭鞚 瓴届榿歆勳澊雮� 鞚挫偓鞐愱矊 歃夑皝鞝侅澑 歆旮� 鞐嗢澊 鞁犼窚 鞛愲掣鞚� 於旉皜頃橂┌, 頃╇硲鞚措倶 鞚胳垬鞕 甏霠澊 鞐嗢姷雼堧嫟. 靹犿儩霅� 氅挫牅 臁绊暛(Rule 506(b))鞚 鞚茧皹 氇鞚� 鞝滍暅頃橂┌, 鞚胳 韴瀽鞛� 霕愲姅 斓滊寑 35氇呾潣 牍勳澑歃� 瓿犼笁 韴瀽鞛愳棎瓴岆 韺愲Г毳� 項堨毄頃╇媹雼�.

Cybin Inc. (CYBN) a d茅pos茅 un formulaire D annon莽ant la cl么ture d鈥檜n placement priv茅 selon la r猫gle 506(b). La soci茅t茅 de th茅rapeutiques psych茅d茅liques bas茅e en Ontario a vendu 50 millions de dollars via un m茅lange de titres de dette, bons de souscription/options et actions sous-jacentes. La premi猫re vente a eu lieu le 30 juin 2025 et l鈥檕ffre ne s鈥櫭﹖endra pas au-del脿 d鈥檜n an. La totalit茅 du montant cibl茅 a 茅t茅 plac茅e, il reste donc 0 dollar.

Principaux termes

  • Taille totale de l鈥檕ffre : 50 000 000 dollars
  • Type de titres : dette et instruments li茅s aux actions
  • Nombre d鈥檌nvestisseurs : 1 (statut accr茅dit茅 non divulgu茅)
  • Commissions de vente : 2 670 000 dollars (Joseph Gunnar & Co., LLC)
  • Frais d鈥檃pporteurs d鈥檃ffaires : 0 dollar
  • Produit destin茅 aux initi茅s : 0 dollar

L鈥櫭﹎etteur a refus茅 de divulguer ses revenus ou la taille de ses actifs. Ce financement apporte de nouveaux capitaux sans paiements imm茅diats aux cadres ou administrateurs et n鈥檈st pas li茅 脿 une fusion ou acquisition. L鈥檈xemption choisie (r猫gle 506(b)) restreint la sollicitation g茅n茅rale et exige des ventes uniquement aux investisseurs accr茅dit茅s ou 脿 un maximum de 35 acheteurs sophistiqu茅s non accr茅dit茅s.

Cybin Inc. (CYBN) hat ein Formular D eingereicht und die Durchf眉hrung einer Privatplatzierung nach Regel 506(b) bekanntgegeben. Das in Ontario ans盲ssige Unternehmen f眉r psychedelische Therapien verkaufte 50 Millionen US-Dollar in einer Mischung aus Schuldtiteln, Warrants/Optionen und zugrunde liegenden Aktien. Der erste Verkauf erfolgte am 30. Juni 2025, und das Angebot wird nicht l盲nger als ein Jahr laufen. Der gesamte Zielbetrag wurde platziert, es verbleiben 0 US-Dollar.

Wichtige Bedingungen

  • Gesamtvolumen des Angebots: 50.000.000 US-Dollar
  • Art der Wertpapiere: Schulden plus aktiengebundene Instrumente
  • Anzahl der Investoren: 1 (Status akkreditiert nicht angegeben)
  • Verkaufsprovisionen: 2.670.000 US-Dollar (Joseph Gunnar & Co., LLC)
  • 痴别谤尘颈迟迟濒耻苍驳蝉驳别产眉丑谤别苍: 0 US-Dollar
  • Ertr盲ge f眉r Insider: 0 US-Dollar

Der Emittent verweigerte Angaben zu Umsatz oder Verm枚genswerten. Die Finanzierung bringt frisches Kapital ohne sofortige Zahlungen an F眉hrungskr盲fte oder Direktoren und ist nicht an eine Fusion oder 脺bernahme gebunden. Die gew盲hlte Befreiung (Regel 506(b)) schr盲nkt die allgemeine Werbung ein und erlaubt Verk盲ufe nur an akkreditierte Investoren oder bis zu 35 nicht akkreditierte, aber versierte K盲ufer.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
X None
Entity Type
0001833141
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
CYBIN INC.
Jurisdiction of Incorporation/Organization
ONTARIO, CANADA
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
CYBIN INC.
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
Toronto ONTARIO, CANADA M5X 1C9 866-292-4601

3. Related Persons

Last Name First Name Middle Name
Drysdale Douglas
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Tziras George
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
So Eric
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Fahel Gabriel
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Glavine Paul
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Cavers Greg
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Bartlone Aaron
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Firestone Theresa
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Lawson Mark
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Froese Grant
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X C19
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Hoskins Eric
Street Address 1 Street Address 2
100 King St. West, Suite 5600
City State/Province/Country ZIP/PostalCode
Toronto ONTARIO, CANADA M5X 1C9
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
AG真人官方 Estate
Commercial
Construction
REITS & Finance
Residential
Other AG真人官方 Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
X
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-06-30 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity Pooled Investment Fund Interests
X Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Joseph Gunnar & Co., LLC 24795
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
1000 RXR Plaza
City State/Province/Country ZIP/Postal Code
Uniondale NEW YORK 11556
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
CONNECTICUT

13. Offering and Sales Amounts

Total Offering Amount $50,000,000 USD
or Indefinite
Total Amount Sold $50,000,000 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $2,670,000 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
CYBIN INC. /s/ Douglas Drysdale Douglas Drysdale CEO 2025-07-09

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


FAQ

How much capital did Cybin Inc. (CYBN) raise in the 2025 Form D offering?

Cybin sold $50,000,000 of securities, with no remaining amount to be sold.

What types of securities were issued in Cybin鈥檚 private placement?

The offering includes debt instruments, warrants/options, and shares issuable upon warrant exercise.

Which Regulation D exemption did Cybin rely on?

The company claimed Rule 506(b), which limits general solicitation and generally restricts sales to accredited investors.

What sales commissions were paid on the offering?

Cybin disclosed $2,670,000 in commissions to Joseph Gunnar & Co., LLC; no finder鈥檚 fees were reported.

How many investors participated in the offering?

The filing lists one investor who purchased the entire $50 million allocation.

Is the financing connected to a merger or acquisition?

No. The filing states the offering is not related to any business combination transaction.

Were any proceeds allocated to Cybin鈥檚 executives or directors?

$0 of the gross proceeds are designated for payments to insiders.
Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Latest News

CYBN Latest SEC Filings

CYBN Stock Data

175.98M
19.22M
107.88%
42.44%
9.45%
Biotechnology
Healthcare
Canada
Toronto